Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR by Taylor-Cousar, Jennifer L et al.
Washington University School of Medicine
Digital Commons@Becker
Open Access Publications
2018
Lumacaftor/ivacaftor in patients with cystic fibrosis
and advanced lung disease homozygous for
F508del-CFTR
Jennifer L. Taylor-Cousar
National Jewish Health
Manu Jain
Northwestern University
Tara Lynn Barto
Baylor College of Medicine
Tarik Haddad
Tampa General Hospital
Jeffrey Atkinson
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Taylor-Cousar, Jennifer L.; Jain, Manu; Barto, Tara Lynn; Haddad, Tarik; Atkinson, Jeffrey; Tian, Simon; Tang, Rui; Marigowda,
Gautham; Waltz, David; Pilewski, Joseph; and VH14-809-106 Investigator Group, ,"Lumacaftor/ivacaftor in patients with cystic
fibrosis and advanced lung disease homozygous for F508del-CFTR." Journal of Cystic Fibrosis.17,2. 228-235. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/6675
Authors
Jennifer L. Taylor-Cousar, Manu Jain, Tara Lynn Barto, Tarik Haddad, Jeffrey Atkinson, Simon Tian, Rui Tang,
Gautham Marigowda, David Waltz, Joseph Pilewski, and VH14-809-106 Investigator Group
This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/6675
Original Article
Lumacaftor/ivacaftor in patients with cystic ﬁbrosis and advanced lung
disease homozygous for F508del-CFTR☆
Jennifer L. Taylor-Cousar a,⁎, Manu Jain b, Tara Lynn Barto c, Tarik Haddad d, Jeffrey Atkinson e,
Simon Tian f, Rui Tang f, Gautham Marigowda f, David Waltz f, Joseph Pilewski g, on behalf of the
VX14-809-106 Investigator Group
a National Jewish Health, 1400 Jackson St., J318, Denver, CO 80206, USA
b Feinberg School of Medicine, Northwestern University, 420 E Superior St., Chicago, IL 60611, USA
c Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA
d Tampa General Hospital, 1 Tampa General Circle, Tampa, FL 33606, USA
e Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, MO 63110, USA
f Vertex Pharmaceuticals Incorporated, 50 Northern Ave., Boston, MA 02210, USA
g University of Pittsburgh School of Medicine, 3550 Terrace St., Pittsburgh, PA 15213, USA
Received 13 July 2017; revised 27 September 2017; accepted 28 September 2017
Available online 8 November 2017
Abstract
Objective: Evaluation of the safety, tolerability, and efﬁcacy of lumacaftor/ivacaftor in patients with cystic ﬁbrosis (CF) with severe lung disease.
Methods: Patients with CF 12 years of age and older, homozygous for F508del-CFTR, with percent predicted forced expiratory volume in 1 second
(ppFEV1) b 40 received lumacaftor 400 mg/ivacaftor 250 mg every 12 h (full dose) for 24 weeks in an open-label, prospective study
(NCT02390219). Dose modiﬁcation to half dose for 1–2 weeks (including at initiation) was permitted. Safety and tolerability were the primary
outcome measures; clinical outcomes were also assessed.
Results: Of 46 patients (initiated on full dose: n = 28; initiated on half dose: n = 18), 35 (76%) completed 24 weeks of treatment. The most
common adverse events included infective pulmonary exacerbation, abnormal respiration, cough, and dyspnea. Compared with patients initiating
on full dose, patients initiating at half dose had less frequent respiratory events (56% vs 71%) of shorter median duration (4 vs 9 days). No dose
modiﬁcations or discontinuations as a result of respiratory events occurred in patients initiating on half dose who were then increased to the full
dose over 2 weeks (versus three each for patients on full dose). Following an initial reduction, ppFEV1 was similar to baseline from week 4
throughout the remainder of the study (least squares mean [95% conﬁdence interval] at week 24: −0.4 [−1.9, 1.1]; p = 0.6249). Compared with the
24 weeks prior to study, the annualized hospitalization rate was lower (rate ratio: 0.41; p = 0.00026) and the duration of intravenous antibiotics
was shorter (mean [standard deviation] difference: −8.52 [24.91] days; p = 0.0369) through study week 24.
Conclusions: Compared with patients with higher lung function, respiratory events were more common in patients with ppFEV1 b 40; aside from
these events, the lumacaftor/ivacaftor safety proﬁle was consistent with previous studies. Results suggest that patients with ppFEV1 b 40 may
beneﬁt from treatment initiation at a lower dose with augmented monitoring before increasing to the full dose.
© 2017 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Cystic ﬁbrosis; F508del; Lumacaftor; Ivacaftor; Severe lung dysfunction; Advanced lung disease
Abbreviations: AE, adverse event; AESI, adverse event of special interest; ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; CF,
cystic fibrosis; CFQ-R, Cystic Fibrosis Questionnaire–Revised; CI, confidence interval; IV, intravenous; IVA, ivacaftor; LS, least squares; LUM, lumacaftor;
MMRM, mixed-effects model for repeated measures; PEx, pulmonary exacerbations; ppFEV1, percent predicted forced expiratory volume in 1 s; q12h, once every
12 h; ULN, upper limit of normal.
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1. Introduction
In patients with cystic fibrosis (CF) who were ≥12 years of age
and homozygous for the F508del-CFTR mutation, lumacaftor/
ivacaftor (LUM/IVA) combination therapy improved lung func-
tion, nutritional status, and pulmonary exacerbations (PEx) com-
pared with placebo (ClinicalTrials.gov identifiers: NCT01807923
andNCT01807949) [1]. These clinical benefits of LUM/IVAwere
sustained for up to 120 weeks on treatment and were associated
with a reduced rate of decline in percent predicted forced expi-
ratory volume in 1 s (ppFEV1) compared with the Cystic Fibrosis
Foundation registry control population [2].
Compared with patients with higher lung function (ie,
ppFEV1 N 40), patients with CF and advanced lung disease
(ppFEV1 b 40) have a greater burden of disease, with an increased
frequency of PEx, worse nutritional status, a greater likelihood of
lung transplantation, and an increased risk of mortality [3–6].
Assessing therapeutic options that are both safe and effective is of
particular interest for patients with CF and advanced lung disease.
While the eligibility criteria to enroll in LUM/IVA pivotal
clinical studies required patients to have a ppFEV1 of 40–90 at
screening [1], a subgroup analysis of phase 3 LUM/IVA clinical
studies examined the safety and efficacy of LUM/IVA in patients
whose ppFEV1 fell below 40 between the screening and baseline
study visits [7]. Treatment benefits in patient with ppFEV1 b 40
were consistent with the overall patient population; however,
an increased incidence of respiratory events, including dyspnea
and chest tightness, were observed [7]. In the clinical practice
setting, there have been reports of increased frequency in res-
piratory adverse events (AEs) in patients with ppFEV1 b 40
initiating treatment with LUM/IVA [8–10]. This study evaluated
the safety and efficacy of LUM/IVA in patients with CF who
were homozygous for the F508del-CFTR mutation and had ad-
vanced lung disease (ppFEV1 b 40) in a prospective, open-label,
24-week clinical study.
2. Methods
This was a phase 3b open-label study of LUM/IVA (Orkambi,
Vertex Pharmaceuticals Incorporated, Boston, MA, USA) in
patients with CF who were homozygous for the F508del-
CFTR mutation and had advanced lung disease (ppFEV1 b 40)
(ClinicalTrials.gov identifier: NCT02390219). The study was
conducted in accordance with Good Clinical Practice guidelines
and was reviewed and approved by institutional review boards.
All patients of age of consent (per local requirements) provided
written informed consent; for patients below the local age of
consent, the patient's parent/legal guardian provided written in-
formed consent, and the patient provided assent when applicable
per local requirements.
This study was conducted at six sites in the United States
between February 19, 2015, and October 3, 2016. Eligible
patients with a diagnosis of CF were 12 years of age or older,
homozygous for the F508del-CFTRmutation, and had a ppFEV1
value b 40 adjusted for age, gender, and height at screening
[11,12] (ppFEV1 ≥ 40 at baseline was permitted). Key exclusion
criteria included (1) current use of invasive mechanical
ventilation; (2) a history of any significant comorbidity or
laboratory abnormality that, in the investigator's judgment, might
have interfered with study assessments or posed an undue risk
for the patient; and (3) abnormal liver (at least 3 of aspartate
aminotransferase [AST], alanine aminotransferase (ALT), gamma-
glutamyl transpeptidase, and alkaline phosphatase ≥ 3 times the
upper limit of normal (ULN); or ALT or AST N 5 times ULN; or
bilirubin N2 times ULN) or renal function (glomerular filtration
rate ≤45 ml/min/1.73 m2, calculated by the Counahan-Barratt
equation [13]). Target enrollment was 100 to 200 patients.
Patients received LUM 400 mg every 12 h (q12h) in com-
bination with IVA 250 mg q12h orally for 24 weeks. Based on
the observation early in this study of a serious AE of respiratory
chest tightness, the study protocol was amended to permit the
option of modification to half dose of study drug (LUM 200 mg
q12h in combination with IVA 125 q12h) for up to 7 days at the
discretion of the treating physician following discussion with and
approval by the medical monitor. This included the option of
initiating the study on half dose of study drug. The dose modifi-
cation could be extended by the treating physician; no patient was
on the modified dose for N15 days.
Patient visits were as follows: screening (within 4 weeks of
study initiation), days 1 and 2, weeks 2, 4, 8, 16, and 24, and
follow-up 4 weeks after the last dose of study drug (Fig. 1).
Spirometry was performed at all patient visits and the Cystic
Fibrosis Questionnaire–Revised (CFQ-R), weight, height, preg-
nancy test, vital signs, pulse oximetry, and information on AEs
and concomitant medications, treatments, and procedures were
collected at all study visits. All questionnaires were completed
before the start of any other assessments scheduled at that visit. In
addition, telephone interviews were conducted at day 3, week 12,
and week 20 to assess patients' status, any AEs, concomitant
medications, treatments, and procedures.
2.1. Outcomes
The primary endpoint was the safety and tolerability of
LUM/IVA based on treatment-emergent AEs (Medical Dictio-
nary for Regulatory Activities [MedDRA] version 19), including
respiratory adverse events of special interest (AESIs; defined as
asthma, bronchial hyperreactivity, bronchospasm, chest discom-
fort, dyspnea, respiration abnormal, and wheezing), clinical
laboratory values (hematology and serum chemistry), and
standard digital 12-lead electrocardiograms. Safety evaluations
also included physical examinations, vital signs (including
nutritional status parameters), pulse oximetry, and day 2
spirometry. Secondary endpoints included absolute change
from baseline in ppFEV1 at each study visit up to week 24,
absolute change from baseline in the CFQ-R respiratory domain
score through week 24, absolute change from baseline in sweat
chloride to the average of day 15 and week 4, total number of
days of intravenous (IV) antibiotics for sinopulmonary signs and
symptoms through week 24, and total number of all-cause
hospitalizations through week 24. Absolute change from
baseline in body mass index (BMI) was evaluated as an
additional safety assessment and was also evaluated for
efficacy.
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2.2. Statistical analysis
Safety was assessed in all patients who received ≥1 dose of
study drug and was analyzed using descriptive statistics. No
formal sample size calculations were performed. Absolute
change from baseline in ppFEV1 was analyzed based on a
mixed-effects model for repeated measures (MMRM) for all
patients who received study drug. The MMRM included
absolute change from baseline in ppFEV1 as the dependent
variable, visit as a fixed effect, and subject as a random effect,
with adjustment for gender and baseline ppFEV1 as a con-
tinuous variable. Absolute change from baseline in the CFQ-R
respiratory domain score and sweat chloride was analyzed
using a similar model, with baseline ppFEV1 replaced in the
model by baseline CFQ-R score and sweat chloride, respec-
tively. A mixed-effects model was used for analysis and was
based on restricted maximum likelihood estimation and
assuming that conditional on fixed and random effects, data
were missing at random, and no imputation of missing data
were done. An additional analysis of BMI was performed using
descriptive statistics.
The total number of days of IV antibiotics for sinopul-
monary signs and symptoms through week 24 was normalized
for time spent in the study by calculating the percentage of days
with IV antibiotics multiplied by 168 (ie, the total study days
expected through week 24). This number was compared with
the normalized total number of days in the 24 weeks prior to
study entry (collected retrospectively) using a paired sample
t-test. Normality was evaluated using a Shapiro–Wilk test
assuming a 0.05 level of significance. A Wilcoxon signed-rank
test was prespecified if the normality assumption was violated.
The number of all-cause hospitalizations through week 24 was
compared with the number in the 24 weeks prior to study entry
(collected retrospectively) and analyzed similarly to total days
with IV antibiotics. An additional analysis was performed to
directly compare calculated event rates, assuming a Poisson
distribution of the number of events in each period (ie, the
24-week study period versus 24 weeks prior to study entry).
3. Results
Forty-six patients enrolled in the study and received at least
one dose of study drug; this was lower than the target
enrollment of 100 to 200 patients and was likely a consequence
of commercial drug availability. Baseline demographics and
clinical characteristics are shown in Table 1. The mean (min,
max) patient age was 32.1 (17, 56) years, ppFEV1 was 29.1
(18.3, 42.0), and BMI was 21.41 (15.65, 28.50) kg/m2. The
Screening LUM 400 mg q12h/IVA 250 mg q12h*
Safety
follow-up
visit
Day
−28
Day
1
Week
24
Week
28
Day
15
Week
4
Week
8
Week
16
Fig. 1. Study design. IVA, ivacaftor; LUM, lumacaftor; q12h, every 12 h. *Dose modification to LUM 200 mg q12h/IVA 125 mg q12h (half dose) was permitted (at
initiation or at any point during the study) at the discretion of the treating physician and after discussion with and approval by the medical monitor.
Table 1
Baseline demographics and characteristics.
Characteristic LUM 200 mg q12h/IVA
125 mg q12h a (N = 18)
LUM 400 mg q12h/IVA
250 mg q12h (N = 28)
LUM/IVA (N = 46)
Male, n (%) 11 (61) 19 (68) 30 (65)
Age, mean (min, max), y 32.9 (17, 56) 31.6 (18, 56) 32.1 (17, 56)
Age groups, n (%), y
b18 1 (6) 0 (0) 1 (2)
≥18 17 (94) 28 (100) 45 (98)
ppFEV1, mean (min, max) 26.9 (18.4, 42.0) 30.6 (18.3, 37.1) 29.1 (18.3, 42.0)
BMI, mean (min, max), kg/m2 20.9 (15.7, 26.1) 21.7 (17.1, 28.5) 21.4 (15.7, 28.5)
Chronic medications, n (%) b
Dornase alfa 16 (89) 22 (79) 38 (83)
Any inhaled antibiotic 16 (89) 23 (82) 39 (85)
Any inhaled bronchodilator 18 (100) 27 (96) 45 (98)
Any inhaled hypertonic saline 14 (78) 22 (79) 36 (78)
Documented on lung transplant waiting list at screening,
n (% of patients with available information)
Yes 1 (25) 1 (4) 2 (7)
No 3 (75) 22 (96) 25 (93)
Information not available 14 5 19
BMI, body mass index; IVA, ivacaftor; LUM, lumacaftor; ppFEV1, percent predicted forced expiratory volume in 1 s.
a Patients who initiated at the modiﬁed dose for 1–2 weeks and then increased to the full dose.
b Includes medications received before the ﬁrst dose of study drug; medications may or may not have continued at the time of ﬁrst dose.
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most common concomitant medications were as expected for a
population with CF with severe lung dysfunction [14]. Of the
46 patients, 35 (76%) completed treatment with LUM/IVA
through 24 weeks, and 11 (24%) discontinued treatment. AEs
were the most common reason for treatment discontinuation
(n = 8; 17%); one patient refused further dosing, 1 patient was
lost to follow-up, and 1 patient was ineligible. The most
common AEs that led to treatment discontinuation were
respiration abnormal (n = 3) and dyspnea (n = 2).
A total of 28 patients (61%) received a starting dose of LUM
400 mg q12h/IVA 250 mg q12h (full dose), and 18 (39%)
received an initial dose of LUM 200 mg q12h/IVA 125 mg
q12h (half dose) for 1–2 weeks followed by escalation to the
full dose. Overall, baseline characteristics were similar between
patients who initiated full-dose LUM/IVA treatment and those
initiated on half dose LUM/IVA (Table 1). The mean (min,
max) ppFEV1 was 26.9 (18.4, 42.0) for patients who started on
the half dose of LUM/IVA and 30.6 (18.3, 37.1) for patients
who started on the full dose.
A summary of AEs is shown in Table 2. The most frequently
reported AEs were infective PEx of CF (59%), abnormal
respiration (57%), cough (46%), dyspnea (43%), increased
sputum (28%), oropharyngeal pain (20%), hemoptysis (17%),
fatigue (15%), headache (15%), decreased appetite (11%),
diarrhea (11%), nasal congestion (11%), nausea (11%), and
wheezing (11%).
Respiratory AESIs for the overall study population and by
treatment initiation dose are shown in Table 3. Overall, the
incidence of respiratory AESIs was 65%, and these events had
an early onset (median [min, max]: 1 [1, 8] days). Of note, a
lower incidence and shorter duration of respiratory AESIs
occurred in patients initiated on half-dose LUM/IVA than in
those initiated on full-dose LUM/IVA (56% vs 71% incidence;
median [min, max] duration of 4.0 [1, 55] days vs 9.0 [1, 61]
days) (Table 3).
Five patients had AEs that necessitated dose reduction
(events leading to dose reduction in N1 patient: respiration
abnormal, n = 3 [7%]; cough, n = 2 [4%]; dyspnea n = 2 [4%];
some patients underwent dose reduction due to multiple AEs).
Seven patients had AEs that necessitated temporary dose
interruption; infective pulmonary exacerbation was the only AE
that led to treatment interruption in N1 patient (n = 2). No dose
modifications or discontinuations due to respiratory AESIs
were required in patients initiating on half dose of LUM/IVA.
In comparison, among patients initiated on full-dose LUM/
IVA, there were three dose modifications and three
discontinuations.
Table 2
Summary of AEs.
LUM/IVA
(N = 46)
n (%)
Any AE 43 (93)
AE leading to treatment interruption 7 (15)
AE leading to dose modification 5 (11)
AE leading to treatment discontinuation 8 (17)
Serious AE 18 (39)
AE leading to death 1 (2)
AE with incidence ≥10%
Infective PEx of CF 27 (59)
Respiration abnormal 26 (57)
Cough 21 (46)
Dyspnea 20 (43)
Sputum increased 13 (28)
Oropharyngeal pain 9 (20)
Hemoptysis 8 (17)
Fatigue 7 (15)
Headache 7 (15)
Decreased appetite 5 (11)
Diarrhea 5 (11)
Nasal congestion 5 (11)
Nausea 5 (11)
Wheezing 5 (11)
AEs were treatment-emergent events and did not necessarily have a causal
relationship with study drug. A patient with multiple events within a category
was counted only once in that category.
AE, adverse event; CF, cystic fibrosis; IVA, ivacaftor; LUM, lumacaftor; PEx,
pulmonary exacerbation.
Table 3
Summary of respiratory AESIs.
LUM 200 mg q12h/IVA
125 mg q12h a (N = 18)
LUM 400 mg q12h/IVA
250 mg q12h (N = 28)
LUM/IVA
Overall (N = 46)
Respiratory AESIs, n (%) b 10 (56) 20 (71) 30 (65)
Dyspnea 6 (33) 14 (50) 20 (43)
Abnormal respiration 9 (50) 17 (61) 26 (57)
Asthma 1 (6) 0 (0) 1 (2)
Wheezing 1 (6) 4 (14) 5 (11)
Duration of events, median (min, max), days 4.0 (1, 55) 9.0 (1, 61) 9.0 (1, 61)
Time to onset of first event, median (min, max), days 1.0 (1, 8) 1.0 (1, 5) 1.0 (1, 8)
Patients with events leading to dose modification, n (%) 0 (0) 3 (11) 3 (7)
Patients with events leading to treatment discontinuation, n (%) 0 (0) 3 (11) 3 (7)
Serious events, n (%) 0 (0) 1 (4) 1 (2)
Treatment-related serious events, n (%) 0 (0) 1 (4) c 1 (2) c
A patient with multiple events within a category was counted only once in that category. AE, adverse event; AESI, adverse event of special interest; IVA, ivacaftor;
LUM, lumacaftor; q12h, once every 12 h.
a Patients who initiated at the modiﬁed dose for 1 to 2 weeks and then increased to the full dose.
b Bronchial hyperreactivity, bronchospasm, and chest discomfort were not reported in any patients.
c Treatment-related serious respiratory AESI was respiration abnormal.
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Overall, no clinically meaningful changes or trends were
observed in clinical laboratory values (hematology and serum
chemistry), electrocardiograms, or vital signs, and no safety
signals were observed in review of spirometry data.
One 33-year-old male patient died following a serious AE of
hemoptysis. The patient received study drug from days 1 to 4,
discontinued treatment from day 4 due to respiratory chest
tightness, and permanently discontinued due to increased
shortness of breath and respiratory chest tightness. Both AEs
were deemed related to study drug by the investigator and
resolved on day 8. The serious AE of hemoptysis occurred
12 days after the last dose of study drug (study day 16), and the
investigator deemed it unlikely to be treatment related.
Five patients (11%) had an ALT or AST elevation N3 times
the upper limit of normal (ULN), including three patients (7%)
who had an ALT or AST elevation N5 times the ULN. One
patient had an AST elevation N3 times the ULN concurrent with
a total bilirubin elevation N2 times the ULN that was observed
at the safety follow-up visit. At screening, all five of these
patients had ALT and AST b 3 times the ULN and bilirubin
b1.5 times the ULN. The patient had a history of increased
hepatic enzymes and bile duct stone and cholecystectomy.
Transaminase elevations were noted at screening and baseline,
and bilirubin was elevated at baseline. The patient permanently
discontinued LUM/IVA after 11 days due to chest pain, fatigue,
dyspnea, and abnormal respiration; these events were deemed
possibly related to study drug. No dose modifications or discon-
tinuations occurred due to elevated transaminases.
There was an initial decrease from baseline in mean absolute
ppFEV1 (least squares [LS] mean change [95% CI] at day 15:
−1.7 [−3.2, −0.1] percentage points; p = 0.0332); ppFEV1
returned to baseline at the week 4 study visit and remained near
baseline through week 24 (LS mean [95% CI] at week 24: −0.4
[−1.9, 1.1]; p = 0.6249) (Fig. 2A). An increase from baseline
in the mean absolute CFQ-R respiratory domain score through
week 24 was seen (LS mean change [95% CI]: 2.5 [−1.0, 5.9]
points) that did not reach statistical significance (p = 0.1554)
(Fig. 2B). Treatment with LUM/IVA resulted in a rapid and
sustained significant reduction in sweat chloride concentration.
The LS mean (95% CI) absolute change from baseline at the
average of day 15 and week 4 was −16.4 (−19.2, −13.7) mmol/L
(p b 0.0001) and at week 24 was −20.2 (−24.3, −16.1) mmol/L
(p b 0.0001) (Fig. 2C). Change from baseline in BMI showed
an initial decrease at day 15 (mean [standard error of the mean]:
−0.16 [0.06] kg/m2) followed by an increase over 24 weeks of
treatment. An increase in BMI was observed by week 16 (0.17
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Fig. 2. Absolute change from baseline in (A) ppFEV1, (B) CFQ-R respiratory domain score, (C) sweat chloride, and (D) BMI at each study visit. Panels A–C are
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[0.16] kg/m2), along with a further increase at week 24 (0.29
[0.17] kg/m2) (Fig. 2D), and BMI remained higher than
baseline at the follow-up visit (0.10 [0.21] kg/m2).
A shorter duration of IV antibiotics and a lower annualized
hospitalization rate were observed during the 24-week treat-
ment period than in the 24 weeks prior to the study. The mean
normalized duration of IV antibiotics through 24 weeks on
study drug was 11.38 days, significantly less than the mean of
19.89 days in the 24 weeks prior to the study (mean difference
[standard error]: −8.52 [3.67]; p = 0.0369) (Fig. 3A). The
number of hospitalizations was lower through week 24 on
study than in the 24 weeks prior to study initiation (23
hospitalizations in 16 patients vs 64 hospitalizations in 21
patients; Wilcoxon signed-rank test, p = 0.0002). The estimat-
ed annualized event rate through 24 weeks on study drug (1.15
events/year) was also lower than in the 24 weeks prior to study
initiation (2.78 events/year; p = 0.00026) (Fig. 3B).
4. Discussion
In this open-label 24-week study, the safety profile of
LUM/IVA in patients with CF and advanced lung disease who
were homozygous for F508del-CFTR was generally consis-
tent with previous clinical studies of LUM/IVA, and the most
frequently observed AEs are common manifestations of CF
(except for oropharyngeal pain) [15]. However, respiratory
events were more frequently reported than in studies that
enrolled patients with ppFEV1 N 40 at baseline [1,2]. Consis-
tent with previous reports [1,2], respiratory events reported in
this study were largely associated with treatment initiation.
The frequency of respiratory-related events was greater than
that observed in a subgroup analysis of phase 3 LUM/IVA
studies examining patients whose ppFEV1 fell to b40 between
screening and baseline [7], although that study encompassed
a different patient population, namely, patients with ppFEV1 N
40 at screening. Indeed, differences suggest that the subgroup
analyzed from previous phase 3 studies (ppFEV1 falling below
40 after baseline) included patients with less advanced lung
disease, which was reflected in their higher baseline ppFEV1
(mean ppFEV1 of 37.2 in the LUM/IVA subgroup vs 29.1 in
the present study) [7]. Moreover, in these subgroup analyses by
Elborn et al., fewer patients with ppFEV1 ≥ 40 at baseline had
respiratory events (dyspnea) than did those with ppFEV1 that
fell below 40 at baseline. The rates of respiratory events
observed here were lower than those from a recent report in
patients with CF and advanced lung disease who initiated
LUM/IVA in real-world clinical practice [10]. Popowicz et al.
reported respiratory events within 24 h of LUM/IVA initiation
in 83% of patients (but 66% at 1 month) as well as acute
deterioration in ppFEV1 (median change [interquartile range] at
2 h post initiation, −19 [−21 to −11] percentage points) [10].
Hubert et al. reported a respiratory event rate of 51% in patients
with CF and advanced lung disease initiating LUM/IVA, with
ppFEV1 improvements over 3 months of treatment comparable
to those observed in the phase 3 studies [1,8]. The differences
in respiratory events in these reports and the current study may
be due to differences in the populations, reporting systems, and/
or disease characteristics assessed.
In a retrospective chart review of patients receiving
LUM/IVA, higher rates of respiratory events were observed
compared with rates observed in LUM/IVA clinical trials in the
subgroup of patients with advanced lung disease, although
treatment was reported to be initiated at a lower dose in such
patients (dose not specified) [9]. The majority of patients in the
Popowicz et al. and Hubert et al. studies were initiated on
full-dose therapy [8,10]. In the present study, some patients
were initiated at a modified dose (LUM 200 mg q12 h/IVA
125 mg q12h [half-dose therapy]). The dose modification
permitted in this study was implemented because the incidence
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of respiratory AEs (eg, dyspnea and shortness of breath)
was noted to be dose dependent in phase 2 studies evaluating
LUM/IVA combination therapy during the LUM monotherapy
phase [16]. This lower initiation dose was associated with a
decreased rate of respiratory events and no treatment discontin-
uations due to respiratory events despite patients having a
somewhat lower mean ppFEV1 at baseline than patients who
started treatment on full dose (LUM 400 mg q12h/IVA 250 mg
q12h). In the current study, overall rates of treatment discontin-
uation due to any AE in patients with ppFEV1 b 40 (8 of 46
patients [17%]) were lower than those observed in the
aforementioned retrospective analyses (25%–32%) [8–10]. It
should be noted that patients enrolled in this prospective trial may
have had higher compliance and a greater willingness to persist
with treatment rather than to discontinue following adverse
events versus patients included in the prior retrospective studies;
this adherence is to be expected when comparing real-world
retrospective studies with prospective clinical trials.
While this study was not powered to assess efficacy,
LUM/IVA was associated with reductions in the duration of
IV antibiotics for exacerbation-related symptoms and in the
number of all-cause hospitalizations. As exacerbations are
associated with a decrease in quality of life [17,18], increased
risk of future exacerbations [19,20], and mortality [21], these
data provide evidence for a potential treatment benefit in this
patient population. Treatment with LUM/IVA was also
associated with an increased BMI over the course of
24 weeks, indicating an amelioration in nutritional status in
these patients with CF with advanced lung disease. Further-
more, this BMI improvement could make patients with
advanced lung disease more desirable transplant candidates.
Although there were no improvements in ppFEV1 over the
course of this study, lung function generally remained near
baseline. A modest change in ppFEV1 (−1.7 percentage
points) was observed early in the course of treatment (day
15). Lung function recovered by the next study visit and
remained near baseline over the 24-week study period.
Decreased sweat chloride following LUM/IVA treatment
further supports the effect of CFTR modulation in these
patients.
The open-label design as well as lack of a direct comparison
to patients with higher lung function (ppFEV1 N 40) limits
interpretation of these findings. As this was primarily a safety
study for this group of patients who were not eligible for
enrollment in the phase III trials for safety reasons, no control
group was included. This design limits the efficacy analyses to
within-group comparisons versus baseline measurements.
Another limitation of this study is the lower-than-projected
patient enrollment, which is partly explained by patients having
had the option of receiving treatment with marketed LUM/IVA
following its rapid US Food and Drug Administration approval
rather than receiving treatment through study enrollment.
However, these data remain informative for this population of
patients with CF with advanced lung disease, who have in-
frequently been assessed. Finally, we note that in analyses
showing reductions in the duration of IV antibiotics and total
number of hospitalizations, comparisons may have been
confounded by differences in data collected during the
24 weeks on study and data collected retrospectively for the
24 weeks before the study. Additional observational studies to
prospectively evaluate exacerbation-related outcomes may be
warranted to confirm these findings.
In summary, in patients with CF and advanced lung disease
with ppFEV1 b 40, the incidence of respiratory events was
higher than that previously observed in patients with less
severe lung dysfunction [1,2,7]. However, the safety profile of
LUM/IVA was generally consistent with the established safety
profile of this CFTR modulator combination, and with the AEs
expected in patients with this degree of lung dysfunction.
Reductions in IV antibiotics for exacerbation-related symptoms
and all-cause hospitalizations were observed and provide
evidence for a potential treatment benefit. Dose modification
using half-dose LUM/IVA before escalating to the full dose was
associated with fewer respiratory events and no treatment
discontinuations, suggesting that patients with ppFEV1 b 40
may benefit from treatment initiation at a lower dose with
augmented monitoring before subsequent increase to the full
dose.
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